Autologous and allogeneic transplantation for aggressive NHL

Cytotherapy

Volumn 4, Issue 3, 2002, Pages 223-240

  Smith, S M ^a   Grinblatt, D ^a   Van Besien, Koen ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

Allogeneic; Autologous; NHL; Transplantation

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CD2 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; NITROSOUREA; NUCLEOSIDE ANALOG; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ALLOTRANSPLANTATION; AUTOGRAFT; AUTOTRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; EARLY DIAGNOSIS; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHATIC LEUKEMIA; MANTLE CELL LYMPHOMA; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PREDICTION; PROGNOSIS; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANTINEOPLASTIC PROTOCOLS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035995205     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402320219745     Document Type: Article

References (131)

1. The rise in incidence of lymphomas in Europe 1985-1992
2. Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995
3. Treatment of non-Hodgkin's lymphoma
4. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity
5. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen
6. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
7. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome
8. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group study
9. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
10. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis
11. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: Durable complete remissions, but a high rate of regimen-related toxicity
12. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
13. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group
14. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
15. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival
16. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
17. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas
18. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
19. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des lymphomes de l'Adulte study
20. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
21. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
22. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study
23. Failure of first-line inductive high-dose chemotherapy in poor risk patients with aggressive lymphoma: Updated results of the randomized LNH93-3 study
24. High dose therapy with autologous stem cell transplantation in aggressive NHL: Results of a randomized multicenter study
25. A multicenter randomized trial by Italian Lymphoma Intergroup (ILI) comparing high dose chemotherapy (hds) with autologous stem cell transplantation (ASCT) vs intensified chemotherapy megaceop in high risk diffuse large cell lymphoma (DLCL): No difference in outcome and toxicity
26. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study
27. Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: Lessons learned and challenges remaining
28. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma
29. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis
30. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
31. Peripheral blood progenitor cells: A replacement for marrow transplantation?
32. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor
33. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy
34. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
35. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: The Hovon 22 study
36. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison
37. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
38. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma
39. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
40. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique
41. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest
42. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: One-half of patients significantly mobilize malignant cells
43. Progenitor and lymphoma cells in blood stem cell harvests: Impact on survival following transplantation
44. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow
45. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged marrow in non-Hodgkin's lymphoma: A double-blind placebo-controlled trial
46. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry
47. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy posttransplantation - Results of a retrospective analysis on 120 patients autografted in a single institution
48. + peripheral blood progenitor cell dose on hematopoietic recovery
49. +Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma
50. Stem cell function and engraftment is not affected 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
51. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
52. Monoclonal antibodies and autologous stem cell transplantation for lymphoma
53. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: The role of preparative regimens
54. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma
55. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial
56. Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens
57. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
58. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
59. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
60. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7
61. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease
62. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma
63. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
64. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
65. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
66. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma
67. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data
68. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation
69. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
70. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity and survival depend on disease histology
71. A prospective, comparative trial of high dose therapy followed by allogeneic versus autologous stem cell transplantation in 100 patients with high risk lymphoma
72. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
73. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
74. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle
75. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma
76. + T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma
77. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: Experience in 44 consecutive patients
78. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
79. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
80. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
81. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
82. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
83. Durable progression free survival (PFS) following non-myeloablative bone marrow transplantation (BMT) for chemorefractory diffuse large B cell lymphoma (B-LCL)
84. Outcome of non-myeloablative stem cell transplantation for NHL is dependent on histology: Good for patients with low grade disease and poor for those with high grade lymphoma
85. Primary mediastinal lymphoma in adults
86. Diffuse histiocytic lymphoma with sclerosis: A clinicopathologic entity frequently causing superior venacaval obstruction
87. Primary mediastinal B-cell lymphoma: A review of pathology and management
88. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: Mediastinal localization predicts for a favorable outcome
89. Primary diffuse large B-cell lymphoma of the mediastinum: Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation
90. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
91. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute
92. Histologic conversion in the non-Hodgkin's lymphomas
93. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
94. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European Bone Marrow Transplant Registry
95. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre
96. Mantle cell lymphoma - An entity comes of age
97. Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants
98. Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients
99. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
100. Does transplantation improve outcome in mantle cell lymphoma? A study from the EBMT
101. Hyper-CVAD and high dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle cell lymphoma
102. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma
103. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission
104. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
105. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3-year follow-up study
106. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
107. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphoma. A single center experience on 18 patients
108. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: The case for purging?
109. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma
110. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma
111. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation
112. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: A case report and literature review on the evidence of GVL effects in MCL
113. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features
114. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives)
115. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)
116. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
117. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
118. Impact of high-dose chemotherapy on peripheral T-cell lymphomas
119. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas
120. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: International index high and high-intermediate risk group
121. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European Group for Blood and Marrow Transplantation
122. Burkitt's lymphoma in adults: A retrospective study of 46 cases
123. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma
124. Treatment of poor prognosis Burkitt's lymphoma in adults with the Societe Francaise d'Oncologie Pediatrique LMB Protocol - A study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC)
125. Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remission
126. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission
127. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)
128. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation
129. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission
130. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
131. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: A report on 62 patients from a single center